Eli Lilly

LLY Healthcare & Pharma 3/10 Low Risk
3/10
Sector avg: 2.8/10

Eli Lilly carries $29.5B in long-term debt, with $8.3B in scheduled principal maturities. Notably, the entire $8.3B maturity schedule falls within five years, creating a concentrated refinancing window. DebtCanary scores LLY at 3/10, suggesting manageable refinancing risk.

Maturity Schedule

Year 1 $781M Year 2 $1.5B Year 3 $2.5B Year 4 $442M Year 5 $3.1B Beyond 5 $0
Period Amount Due % of Total
Year 1 (0-12 months) $781M 9.4%
Year 2 (12-24 months) $1.5B 18.3%
Year 3 (24-36 months) $2.5B 30.2%
Year 4 (36-48 months) $442M 5.3%
Year 5 (48-60 months) $3.1B 36.9%
Beyond 5 Years N/A N/A
Total Scheduled Maturities $8.3B 100.0%

Key Metrics

Total Long-Term Debt
$29.5B
Near-Term (12mo)
$781M
Interest Coverage
N/A
Debt/Equity
1.11
Cash Coverage
9.31x
Operating Income
N/A

Score Components

Component Value Weight
Near-Term Maturity Concentration 9.4% 30%
Interest Coverage Ratio N/A 25%
Debt-to-Equity Ratio 1.11 25%
Cash Coverage of Near-Term Debt 9.31x 20%

Related Companies

Johnson & Johnson
JNJ
1/10
Debt: $41.4B 12mo: $2.0B
Pfizer
PFE
4/10
Debt: N/A 12mo: $3.0B
AbbVie
ABBV
4/10
Debt: $64.5B 12mo: $6.0B
Merck &
MRK
1/10
Debt: N/A 12mo: $2.6B
Bristol Myers Squibb
BMY
5/10
Debt: $44.8B 12mo: $2.0B
Amgen
AMGN
6/10
Debt: $54.6B 12mo: $4.6B
Gilead Sciences
GILD
3/10
Debt: $24.9B 12mo: $2.8B
Regeneron Pharmaceuticals
REGN
1/10
Debt: N/A 12mo: N/A

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Fiscal period end: 2025-12-31. Filing date: 2026-02-12. Data last fetched: 2026-03-29. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Partial.
View SEC EDGAR filings for Eli Lilly →